Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD UCSF
Dates
study started
completion around

Description

Summary

Official Title

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Keywords

Advanced Non-small Cell Lung Cancer, HER2 Mutation, NSCLC, ERBB2 mutation, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Carboplatin, Pembrolizumab, Pemetrexed, BAY2927088, Cisplatin

Eligibility

Locations

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Bayer
Links
Click here to find further information and, after study completion, the study results according to Bayer's transparency standards.
ID
NCT06452277
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 278 study participants
Last Updated